WO2008038807A1 - External composition for skin - Google Patents
External composition for skin Download PDFInfo
- Publication number
- WO2008038807A1 WO2008038807A1 PCT/JP2007/069111 JP2007069111W WO2008038807A1 WO 2008038807 A1 WO2008038807 A1 WO 2008038807A1 JP 2007069111 W JP2007069111 W JP 2007069111W WO 2008038807 A1 WO2008038807 A1 WO 2008038807A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- bht
- external
- composition
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000002245 particle Substances 0.000 claims description 32
- 229920003169 water-soluble polymer Polymers 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 38
- 239000007787 solid Substances 0.000 abstract description 9
- 230000000638 stimulation Effects 0.000 abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 208000006877 Insect Bites and Stings Diseases 0.000 abstract description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 49
- 230000007803 itching Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 230000007794 irritation Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 10
- -1 polyethylene Polymers 0.000 description 10
- 239000003814 drug Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000005722 itchiness Effects 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- ZRTQSJFIDWNVJW-WYMLVPIESA-N Lanoconazole Chemical compound ClC1=CC=CC=C1C(CS\1)SC/1=C(\C#N)N1C=NC=C1 ZRTQSJFIDWNVJW-WYMLVPIESA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- ARZLUCYKIWYSHR-UHFFFAOYSA-N hydroxymethoxymethanol Chemical compound OCOCO ARZLUCYKIWYSHR-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229950010163 lanoconazole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Definitions
- the present invention relates to a composition for external use on skin having an itching suppression effect, a massage effect and the like.
- the power of performing massage or the like to obtain a beauty or relaxation effect For example, the power of performing massage or the like to obtain a beauty or relaxation effect.
- water-insoluble particles are blended as a scrub agent in order to exert a massage effect by physical stimulation.
- scrubbing agents hard scrubbing agents such as polyethylene beads, talmi shell grains, and crystalline cellulose are widely used. Although hard scrubs are excellent in removing dirt on the skin and in massaging the skin, there are cases in which unpleasant skin irritation or foreign body sensation is felt during use.
- itch is defined as “a sensation that causes the skin to break! /, And! /”, And is generally an unpleasant sensation.
- Symptoms associated with “itch” include various forms such as atopic dermatitis, urticaria, insect bites, dry skin, and hypersensitive skin.
- antihistamines, local anesthetics, moisturizing Agents are used. However, since they penetrate into the inner surface of the skin and involve a scientific approach, it takes time to take effect.
- Patent Document 1 discloses an external preparation for skin containing natural oils and fats and antioxidants.
- butylhydroxytoluene is generally added in an amount of about 0.0 ;! to 1% as a preservative, stabilizer, antioxidant and the like.
- these external preparations have also been unable to effectively suppress the skin rather than those intended to irritate the skin.
- Patent Document 1 JP 2000-159678 Disclosure of the invention
- the main object of the present invention is to provide an external preparation for skin that gives skin irritation by application and exhibits a comfortable massage effect.
- Another object of the present invention is to provide an external composition for skin, which can replace itching caused by insects and hypersensitivity skin with irritation, and can effectively suppress itching. Is.
- BHT ptylhydroxytonolene
- the present invention provides the following external composition for skin.
- Item 1 A composition for external use on skin, characterized by containing solid-state butylhydroxytoluene (hereinafter referred to as BHT).
- BHT solid-state butylhydroxytoluene
- Item 2 The external composition for skin according to Item 1, wherein the particle size of BHT is 1000 m or less.
- Item 4 The composition for external application to skin according to any one of Items 1 to 3, wherein the BHT content is 10 to 40% by weight.
- Item 5 The external composition for skin according to any one of Items 1 to 4, further comprising a water-soluble polymer.
- the invention's effect [0009]
- the external composition for skin according to the present invention is applied directly to the skin, and the BHT in a solid state physically stimulates the skin, so that an appropriate massage stimulus can be given to the skin.
- the composition for external use of the skin of the present invention when applied to an affected area having itching, it can be replaced with a feeling of irritation in a short time by physical stimulation of BHT in a solid state, and the itching is effectively suppressed. can do.
- composition for external use of the skin of the present invention is characterized mainly by containing BHT in a solid state.
- BHT BHT
- the antipruritic agent of this invention contains BHT as an essential component.
- Ptylhydroxytoluene is a compound having a white crystal shape, and both 1S, also called dibutylhydroxytoluene, refer to the same compound ([(CH 3) C] C H (CH 2) OH).
- BHT traditionally makeup
- antioxidants and stabilizers for foods, pharmaceuticals, foods and the like.
- BHT commercially available ones can be used.
- butyl hydroxytoluene (Sanei Chemical Co., Ltd.), dibutylhydroxytoluene (Eastman Chemica Norre Japan Co., Ltd., Ueno Pharmaceutical Co., Ltd.) API Corporation, Sumitomo Chemical Co., Ltd., Nagase Sangyo Co., Ltd., JGC Universal Co., Ltd., Mitsubishi Wel Pharma Co., Ltd.).
- the particle size of BHT used in the present invention is about lOOOO ⁇ m or less, preferably about 1000 to 50 to 111, more preferably about 1000 to; about 100 to m, more preferably about 1000 to; About 180 in.
- BHT having each particle diameter can be obtained by pulverizing BHT with a mortar or the like and then applying it to a sieve having each diameter.
- Preferred combinations include, for example, (a) 501-; about 1000 m A combination of BHT with a particle size of and ⁇ having a particle size of about 350 to 500 ⁇ m; (b) BHT with a particle size of less than 350 [Im and a particle size of about 350 to 500 ⁇ m A combination of BHT having
- the blending ratio of BHT having each particle size is appropriately set as long as the substitution effect on the irritating feeling of itchiness can be exhibited.
- BHT having a particle size of about 501 to 1000 m is set to 0.
- the amount of BHT in the external composition for skin of the present invention is about 10 to 40% by weight, preferably about 15 to 35% by weight, more preferably about 20 to 30% by weight. With such a blending amount, the massage effect and the antipruritic effect due to skin irritation can be exhibited more significantly while maintaining the stability as a preparation.
- the composition for external use of the present invention preferably contains alcohol in addition to the BHT.
- alcohol By blending alcohol, solid-state BHT can be dispersed favorably, and the skin can be uniformly and moderately stimulated.
- the alcohol used in the present invention is not particularly limited as long as it is commonly used in the fields of cosmetics and pharmaceuticals. For example, methanol, ethanol, propanol, isopropanol, butanol, isobutanol and the like are used.
- Lower alcohol having 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms; propylene glycol, dipropylene glycol, glycerin, 1,3-butylene glycol, butylene glycol, concentrated glycerin, polyethylene glycol, maltitol, mannitol, sorbitol, etc.
- Examples include polyhydric alcohols. these May be used alone or in combination of two or more.
- the lower alcohol may be anhydrous or hydrated. In the present invention, it is preferable to use (hydrous) ethanol, absolute ethanol, or isopropanol!
- the blending amount of alcohol in the composition for external use of the present invention is about 0 to 45% by weight, preferably about 4 to 40% by weight, more preferably about 4 to 35% by weight.
- the blending ratio of BHT and alcohol in the external composition for skin of the present invention is such that when BHT is 1 part by weight, alcohol is about 3 parts by weight or less, preferably about 2 parts by weight or less, and more preferably about 1 part by weight or less. With such a blending ratio, the solid state of BHT can be maintained and an appropriate stimulus can be given to the skin.
- the external composition for skin of the present invention may contain water, a water-soluble polymer, or the like, if necessary.
- Conventionally known water-soluble polymers can be used, for example, carboxyvininole polymer, polyvinyl alcohol, polyvinyl methyl ether, polyvinylinoxychetyl cellulose, pullulan, agar, gelatin, alginic acid and its salts, carrageen Examples include naan and gums. These may be used alone or in combination of two or more.
- the amount of water in the external composition for skin of the present invention is about 25 to 89.5% by weight, preferably about 27 to 80.2% by weight, more preferably about 28 to 75% by weight;
- the amount of the conductive polymer to be combined is about 0.5 to 5% by weight, preferably about 0.8 to 4% by weight, and more preferably about 1 to 3% by weight.
- Typical formulation examples of the present invention 10 to 40 weight BHT 0/0, the Anorekonore 0-45 wt%, a water-soluble polymer 0.5 to 5% by weight, water 25-89.
- a composition for external use containing 5% by weight is exemplified.
- the composition for external use of the skin of the present invention includes various components generally used in cosmetics, quasi-drugs, pharmaceuticals, aqueous components, oil-based components, moisturizing components, moisturizing components, and so on.
- Forms, thickeners, preservatives, antioxidants, pH adjusters, carriers, fragrances, colorants, drugs and the like can be prepared in various dosage forms alone or in combination of two or more.
- the composition for external use of the skin of the present invention includes a known local anesthetic and antibacterial agent within the range not impairing the effects of the present invention.
- local anesthetics such as lidocaine, dibu force in, dibu force in hydrochloride, diphenhydramine, ethyl aminobenzoate, desitthecin; chlorpheniramine maleate, diphenhydramine, diphenhydramine hydrochloride, glycyrrhetinic acid, glycyrrhizin
- Anti-inflammatory agents such as dipotassium phosphate, monoammonium glycyrrhizinate, allantoin, methyl salicylate; 1-menthol nole, dl-menthol nole, camphor, dl-strengthen, lactic acid menthylate, etc .
- Moisturizers such as urea, salicylic acid, sodium hyaluronate
- Bactericides such as isopropylmethyl phenol, quaternary ammonium salts (benzalkonium chloride, benzethonium chloride, etc.), chlorhexidine hydrochlor
- Examples of the dosage form of the external composition for skin of the present invention include force S that can be prepared into a conventionally known dosage form according to the method of use and application, such as an ointment, lotion, gel, aerosol, and the like. It is done.
- the external composition for skin of the present invention contains an appropriate amount of a base for obtaining a desired dosage form.
- a base for example, but not limited to, paraffin, petrolatum, squalane, norafin, white wax, plastibase, polyethylene glycolenore, macrogonole, lauromacronore, silicone oil, silicone, polysorbate, polyoxyethylene hydrogenated castor oil, Oil bases such as olive oil, cottonseed oil, soybean oil, coconut oil; higher alcohols such as cetanol and stearyl alcohol; fatty acid esters (such as isopropyl myristate and sorbitan fatty acid ester), higher fatty acid salt emulsifiers, highly refined egg yolk lecithin , Soybean lecithin, refined soybean lecithin, white beeswax, propylene carbonate, egg yolk phospholipid, egg yolk oil, coconut oil fatty acid, sodium lauryl sulfate, other ionic and nonionic surfactants
- the composition for external use of the present invention can be prepared by mixing and preparing the above components according to a conventionally known method. Conditions such as temperature in preparation, order of addition of each component, mixing time, etc. should be set as appropriate based on the common general technical knowledge according to the physical or scientific properties of each component, concentration, instrument stress, etc. Is not particularly limited.
- the external preparation for skin of the present invention comprises For example, it can be prepared by dissolving components soluble in water and alcohol, mixing them and stirring them uniformly, and finally adding BHT.
- composition for external use of the skin of the present invention can be applied as an antipruritic agent, athlete's foot drug or the like to a place where itching occurs.
- the application target is not particularly limited as long as it is used for this purpose, but for example, when used as an antipruritic agent, it can be applied to symptom accompanied by itching, insect bite, dry skin, hypersensitive skin, etc. .
- itch refers to "a feeling that causes the idea of wanting to break through the skin” as described above.
- an appropriate amount of the external composition for skin of the present invention may be spread over the itchy part of the skin.
- the solid BHT can physically irritate the itchy part of the skin, replace the itching with a feeling of irritation, and suppress the itching without further rebating.
- “replacing itching with a sense of irritation” refers to making the skin sensation in a short-term (instantaneous) state of feeling an irritation (feeling itchy) other than “itching”.
- the skin irritation by the external preparation for skin of the present invention is an appropriate stimulation without damaging the skin, and thus can be used for promoting blood circulation at the application site. Therefore, the external preparation for skin of the present invention can also be used as a massage agent, an external anti-inflammatory analgesic or the like.
- the obtained external composition for skin was stored at room temperature (about 25 ° C) for 1 week, and its properties were visually confirmed to evaluate the stability. Specifically, dispersibility (presence / absence of particle settling and agglomeration (aggregation of particles)), shape retention (presence / absence of obvious changes compared to initial properties such as viscosity reduction), and particles are solid It was confirmed whether the properties were maintained (softening / dissolution). When there was no change in any of these properties, it was marked as ⁇ , and when any one of the changes was confirmed, it was marked as X.
- composition for external use with a stability evaluation result of “ ⁇ ” was applied to the affected area of 10 subjects complaining of itching caused by insect bites, etc., and it was easy to apply (one point when it was difficult to apply) 5 points when easy to apply), replacement of itching with irritation (1 point when not replaced with irritation, 5 points when replaced with irritation) and anti-itching effect (when itching does not stop) 1 point and 5 points when itching stops) were evaluated in 5 stages each.
- composition for external application on skin was applied to the skin of 10 healthy subjects, and with regard to comfortable physical irritation (1 point when not felt, 5 points when felt) Evaluation was performed.
- Table 1 shows the evaluation results.
- CVP represents carboxybulle polymer and PG represents propylene glycol.
- composition for external use with skin containing particles other than BHT (Comparative Examples;! -32) was also evaluated in the same manner. The results are shown in Table 2-1 and Table 2-2 below.
- CVP represents a carboxybule polymer
- PG represents propylene glycol
- Comparative Examples 9 to 13, 16, 25 to 29, and 32 are compositions for external use in skin that contain conventionally known particles. These external preparations for skin were relatively stable and good, but all of them had a replacement effect on the irritating feeling of itchiness and a pleasant stimulating action. In the preparations in which BHT was dissolved, it was not possible to obtain a sensation of itchiness or a pleasant irritation (data not shown).
- the composition for external use of the skin of the present invention has an excellent anti-itching effect as well as a temporary anti-itching effect of replacing itching with a stimulating feeling. That is, the external composition for skin of the present invention has an immediate and long-lasting itch suppression effect.
- CVP carboxybutyl polymer
- PG propylene glycol
- HPC hydroxypropyl cellulose
- DPG dipropylene glycol
- 1,3-BG 1,3-butylene glycol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
It is intended to provide an external composition for skin capable of imparting a physical feeling of stimulation to the skin, replacing pruritus such as particularly insect bites or hypersensitive skin with a feeling of stimulation, and effectively suppressing pruritus. The external composition for skin is characterized by containing butylhydroxytoluene in a solid state.
Description
明 細 書 Specification
皮膚外用組成物 Skin external composition
技術分野 Technical field
[0001] 本発明は、痒み抑制効果、マッサージ効果等を有する皮膚外用組成物に関する。 [0001] The present invention relates to a composition for external use on skin having an itching suppression effect, a massage effect and the like.
背景技術 Background art
[0002] 皮膚を物理的に刺激することは、血行促進、マッサージ、かゆみの抑制(鎮痒)など の効果があることが知られてレ、る。 [0002] Physically stimulating the skin is known to have effects such as blood circulation promotion, massage, and itching suppression (antipruritus).
[0003] 例えば、美容やリラックス効果を得るためにマッサージなどが行われている力 その 際に、物理的な刺激によるマッサージ効果を発揮するために水不溶性粒子がスクラ ブ剤として配合されている。スクラブ剤としては、ポリエチレンビーズ、タルミ殻粒、結 晶性セルロース等の硬スクラブ剤が汎用されている。硬スクラブ剤は、皮膚上の汚れ を除去する効果や皮膚のマッサージ効果に優れるものの、使用時に不快な皮膚刺 激を感じたり、異物感を感じたりする場合があった。 [0003] For example, the power of performing massage or the like to obtain a beauty or relaxation effect. At that time, water-insoluble particles are blended as a scrub agent in order to exert a massage effect by physical stimulation. As scrubbing agents, hard scrubbing agents such as polyethylene beads, talmi shell grains, and crystalline cellulose are widely used. Although hard scrubs are excellent in removing dirt on the skin and in massaging the skin, there are cases in which unpleasant skin irritation or foreign body sensation is felt during use.
[0004] また、「かゆみ」は、「皮膚を搔破した!/、と!/、う観念を起こさせる感覚」と定義され、概 ね不快となる感覚である。「かゆみ」を伴う症状としては、例えばアトピー性皮膚炎、し つしん、虫さされ、乾燥肌、知覚過敏肌等の多様なものがあり、その病態によって、抗 ヒスタミン剤、局所麻酔剤、保湿剤等が使用されている。し力もながら、それらは、皮 膚内面に浸透し、また科学的なアプローチを伴うものであるため、効力発揮まで時間 を要する。 [0004] In addition, “itch” is defined as “a sensation that causes the skin to break! /, And! /”, And is generally an unpleasant sensation. Symptoms associated with “itch” include various forms such as atopic dermatitis, urticaria, insect bites, dry skin, and hypersensitive skin. Depending on the condition, antihistamines, local anesthetics, moisturizing Agents are used. However, since they penetrate into the inner surface of the skin and involve a scientific approach, it takes time to take effect.
[0005] この様な背景から、かゆみを短時間で効果的に抑制し得る皮膚外用組成物が求め られていた。かゆみを抑制する目的で使用される皮膚外用剤は、従来から数多く知ら れており、例えば、特許文献 1には天然油脂と抗酸化剤を配合した皮膚外用剤が開 示されている。このような皮膚外用剤中には、保存剤、安定化剤、抗酸化剤等として 一般的にブチルヒドロキシトルエンが 0. 0;!〜 1 %程度配合されている。しかしながら 、これらの外用剤についても皮膚を刺激することを目的としたものではなぐ効果的に 鎮痒することができな力 た。 [0005] Against this background, there has been a demand for an external composition for skin that can effectively suppress itching in a short time. Many external preparations for skin used for the purpose of suppressing itching have been known. For example, Patent Document 1 discloses an external preparation for skin containing natural oils and fats and antioxidants. In such external preparations for skin, butylhydroxytoluene is generally added in an amount of about 0.0 ;! to 1% as a preservative, stabilizer, antioxidant and the like. However, these external preparations have also been unable to effectively suppress the skin rather than those intended to irritate the skin.
特許文献 1 :特開 2000— 159678
発明の開示 Patent Document 1: JP 2000-159678 Disclosure of the invention
発明が解決しょうとする課題 Problems to be solved by the invention
[0006] 本発明は、塗布によって皮膚刺激を与え、快適なマッサージ効果を発揮する皮膚 外用剤を提供することを主な目的とする。また、本発明は、虫さされ、知覚過敏肌等 のかゆみを刺激感に置換し、さらに効果的にかゆみを抑制することが可能な皮膚外 用組成物を提供することを主な目的とするものである。 [0006] The main object of the present invention is to provide an external preparation for skin that gives skin irritation by application and exhibits a comfortable massage effect. Another object of the present invention is to provide an external composition for skin, which can replace itching caused by insects and hypersensitivity skin with irritation, and can effectively suppress itching. Is.
課題を解決するための手段 Means for solving the problem
[0007] 本発明者は、上記課題を解決すべく鋭意検討を重ねた結果、プチルヒドロキシトノレ ェン(以下 BHTと略記することがある)を固体状態で外用剤に配合し、これを皮膚に 適用することによって、マッサージ効果ゃ鎮痒効果が得られることを見出した。 BHT は化粧品等の外用剤に広く用いられる成分であるが、専ら酸化防止、安定化等を期 待して配合される成分であり、マッサージや鎮痒等を目的として用いることは全く想起 されていな力、つた。本発明は、このような知見に基づき、さらに研究を重ねた結果、完 成されたものである。 [0007] As a result of intensive studies to solve the above-mentioned problems, the present inventor formulated ptylhydroxytonolene (hereinafter sometimes abbreviated as BHT) into an external preparation in a solid state, and this was applied to the skin. It has been found that a massage effect can be obtained by applying it. BHT is a component that is widely used in external preparations such as cosmetics, but it is a component that is formulated exclusively for anti-oxidation, stabilization, etc., and it has never been recalled for use for purposes such as massage or wrinkles. Power, ivy. The present invention has been completed as a result of further research based on such knowledge.
[0008] 本発明は、以下の皮膚外用組成物を提供する。 [0008] The present invention provides the following external composition for skin.
項 1. 固体状態のプチルヒドロキシトルエン (以下、 BHTと示す)を含有することを特 徴とする皮膚外用組成物。 Item 1. A composition for external use on skin, characterized by containing solid-state butylhydroxytoluene (hereinafter referred to as BHT).
項 2· BHTの粒子径が 1000 m以下であることを特徴とする項 1に記載の皮膚外用 組成物。 Item 2. The external composition for skin according to Item 1, wherein the particle size of BHT is 1000 m or less.
項 3.粒子径 350 未満の BHT、粒子径 350〜500 の BHT、粒子径 50;!〜 1 000 mの BHTを 1種又は 2種以上組み合わせて配合することを特徴とする項 1又 は 2に記載の皮膚外用組成物。 Item 3. A BHT having a particle size of less than 350, a BHT having a particle size of 350 to 500, a particle size of 50;! To 1 000 m, or a combination of two or more BHTs. The composition for external application to skin.
項 4· BHTの含有量が 10〜40重量%である項 1〜3のいずれかに記載の皮膚外用 組成物。 Item 4. The composition for external application to skin according to any one of Items 1 to 3, wherein the BHT content is 10 to 40% by weight.
項 5.さらに水溶性高分子を含有する、項 1〜4のいずれかに記載の皮膚外用組成 物。 Item 5. The external composition for skin according to any one of Items 1 to 4, further comprising a water-soluble polymer.
発明の効果
[0009] 本発明の皮膚外用組成物は、直接皮膚に適用するものであり、固体状態の BHT が皮膚を物理的に刺激することによって皮膚に適度なマッサージ刺激を与えることが できる。また、本発明の皮膚外用組成物を、かゆみを有する患部に適用すると、固体 状態の BHTの物理的な刺激によって、短時間でかゆみを刺激感に置換することが でき、かゆみを効果的に抑制することができる。 The invention's effect [0009] The external composition for skin according to the present invention is applied directly to the skin, and the BHT in a solid state physically stimulates the skin, so that an appropriate massage stimulus can be given to the skin. In addition, when the composition for external use of the skin of the present invention is applied to an affected area having itching, it can be replaced with a feeling of irritation in a short time by physical stimulation of BHT in a solid state, and the itching is effectively suppressed. can do.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0010] 本発明の皮膚外用組成物は、 BHTを固体状態で含有することを主な特徴としてい る。以下、本発明の皮膚外用組成物の各成分、製造方法、適用等について説明する[0010] The composition for external use of the skin of the present invention is characterized mainly by containing BHT in a solid state. Hereinafter, each component, manufacturing method, application, etc. of the composition for external use of the present invention will be described.
〇 本発明の鎮痒剤は、 BHTを必須の成分として含有する。プチルヒドロキシトルエン は、白色結晶の形状を有する化合物であり、ジブチルヒドロキシトルエンとも呼ばれる 1S 両者は同じ化合物([ (CH ) C] C H (CH ) OH)を指す。 BHTは、従来、化粧 * The antipruritic agent of this invention contains BHT as an essential component. Ptylhydroxytoluene is a compound having a white crystal shape, and both 1S, also called dibutylhydroxytoluene, refer to the same compound ([(CH 3) C] C H (CH 2) OH). BHT, traditionally makeup
3 3 2 6 2 3 3 3 2 6 2 3
料、医薬品、食品等の酸化防止剤、安定化剤等の用途で配合されている。 It is blended for uses such as antioxidants and stabilizers for foods, pharmaceuticals, foods and the like.
[0011] BHTとしては、商業的に入手可能なものを用いることができ、例えば、プチルヒドロ キシトルエン(三栄化工株式会社)、ジブチルヒドロキシトルエン (イーストマン ケミカ ノレ ジャパン株式会社、上野製薬株式会社、株式会社エーピーアイコーポレーション 、住友化学工業株式会社、長瀬産業株式会社、 日揮ユニバーサル株式会社、三菱 ゥエルファーマ株式会社)等が挙げられる。 [0011] As BHT, commercially available ones can be used. For example, butyl hydroxytoluene (Sanei Chemical Co., Ltd.), dibutylhydroxytoluene (Eastman Chemica Norre Japan Co., Ltd., Ueno Pharmaceutical Co., Ltd.) API Corporation, Sumitomo Chemical Co., Ltd., Nagase Sangyo Co., Ltd., JGC Universal Co., Ltd., Mitsubishi Wel Pharma Co., Ltd.).
[0012] 本発明に使用される BHTの粒子径は、 lOOO ^ m以下程度であり、好ましくは 100 0〜50〃 111程度、より好ましくは 1000〜; 100〃 m程度、さらに好ましくは 1000〜; 180 in程度である。ここで、各粒子径を有する BHTは、 BHTを乳鉢などで粉砕した後 、各径を有する篩等に供することで得ることができる。 [0012] The particle size of BHT used in the present invention is about lOOOO ^ m or less, preferably about 1000 to 50 to 111, more preferably about 1000 to; about 100 to m, more preferably about 1000 to; About 180 in. Here, BHT having each particle diameter can be obtained by pulverizing BHT with a mortar or the like and then applying it to a sieve having each diameter.
[0013] また、本発明においては異なる粒子径を有する BHTを組み合わせて用いることに よって、より優れた効果が得られることから、 2種以上の粒子径を有する BHTを組み 合わせて配合することが望ましぐ例えば、粒子径 350 111未満の BHT、粒子径 35 0—500 ^ HK BHT,粒子径 50;!〜 1000 mの BHTを 2種以上組み合わせて用 いること力 Sできる。好ましい組み合わせとしては、例えば、(a) 501〜; 1000 m程度
の粒子径を有する BHT及び 350〜500 μ m程度の粒子径を有する ΒΗΤの組み合 わせ;(b) 350 [I m未満程度の粒子径を有する BHT及び 350〜500 μ m程度の粒 子径を有する BHTの組み合わせ等が挙げられる。 [0013] Further, in the present invention, by using a combination of BHTs having different particle sizes, a more excellent effect can be obtained. Therefore, it is possible to combine BHTs having two or more types of particle sizes in combination. Desirably, for example, BHT having a particle size of less than 350 111, particle size of 350-500 ^ HK BHT, particle size of 50;! Preferred combinations include, for example, (a) 501-; about 1000 m A combination of BHT with a particle size of and ΒΗΤ having a particle size of about 350 to 500 μm; (b) BHT with a particle size of less than 350 [Im and a particle size of about 350 to 500 μm A combination of BHT having
[0014] 2種以上の粒子径を有する BHTを組み合わせて用いる場合、各粒子径を有する B HTの配合割合は、痒みの刺激感への置換作用を発揮し得る範囲であれば適宜設 定すること力できる力 例えば、上記(a)の組み合わせであれば、 350〜500 111程 度の粒子径を有する BHT1重量部とした場合、 501〜; 1000 m程度の粒子径を有 する BHTを 0. ;!〜 10重量部程度、好ましくは 0. 25-7. 5重量部程度、より好ましく は 0· 5〜5重量部程度;上記(b)の組み合わせであれば、 350〜500 111程度の粒 子径を有する BHT1重量部とした場合、 350 m未満程度の粒子径を有する BHT を、 0. ;!〜 10重量部程度、好ましくは 0. 25-7. 5重量部程度、より好ましくは 0. 5 〜 5重量部程度の割合で組み合わせて用いる。 [0014] When two or more types of BHT having a particle size are used in combination, the blending ratio of BHT having each particle size is appropriately set as long as the substitution effect on the irritating feeling of itchiness can be exhibited. For example, in the case of the combination (a) above, when 1 part by weight of BHT having a particle size of about 350 to 500 111 is used, BHT having a particle size of about 501 to 1000 m is set to 0. About 10 to 10 parts by weight, preferably about 0.25 to 7-5 parts by weight, more preferably about 0.5 to 5 parts by weight; with the combination (b) above, about 350 to 500 111 grains In the case of 1 part by weight of BHT having a child diameter, BHT having a particle diameter of less than 350 m is about 0.;! To about 10 parts by weight, preferably about 0.25-7. 5 parts by weight, more preferably 0. Used in combination at a ratio of about 5 to 5 parts by weight.
[0015] 本発明の限定的解釈を望むものではないが、粒子径が不均一な BHTを配合する ことによって、より顕著に本発明の効果が奏され得る。 [0015] Although a limited interpretation of the present invention is not desired, the effects of the present invention can be more remarkably achieved by blending BHT having a non-uniform particle size.
[0016] 本発明の皮膚外用組成物における BHTの配合量は、 10〜40重量%程度、好まし くは 15〜35重量%程度、より好ましくは 20〜30重量%程度である。このような配合 量であれば、製剤としての安定性を保ちつつ、皮膚刺激によるマッサージ効果ゃ鎮 痒効果がより顕著に発揮され得る。 [0016] The amount of BHT in the external composition for skin of the present invention is about 10 to 40% by weight, preferably about 15 to 35% by weight, more preferably about 20 to 30% by weight. With such a blending amount, the massage effect and the antipruritic effect due to skin irritation can be exhibited more significantly while maintaining the stability as a preparation.
[0017] (2)その他の成分 [0017] (2) Other ingredients
本発明の皮膚外用組成物には、前記 BHTの他、アルコールが含有されることが好 ましい。アルコールを配合することで、固体状態の BHTを好適に分散させることがで き、皮膚を満遍なぐかつ適度に刺激することが可能となる。本発明において使用さ れるアルコールとしては、化粧料、医薬品の分野において一般的に使用されているも のであれば特に限定されないが、例えば、メタノール、エタノール、プロパノール、イソ プロパノール、ブタノール、イソブタノール等の炭素数 1〜6、好ましくは炭素数 1〜3 の低級アルコール;プロピレングリコール、ジプロピレングリコール、グリセリン、 1 , 3— ブチレングリコール、ブチレングリコール、濃グリセリン、ポリエチレングリコール、マル チトール、マンニトール、ソルビトール等の多価アルコールなどが例示される。これら
を 1種単独で使用してもよぐ 2種以上を組み合わせて用いてもよい。また、低級アル コールは、無水、含水の別を問わない。本発明においては、(含水)エタノール、無水 エタノール、イソプロパノールを用いることが好まし!/、。 The composition for external use of the present invention preferably contains alcohol in addition to the BHT. By blending alcohol, solid-state BHT can be dispersed favorably, and the skin can be uniformly and moderately stimulated. The alcohol used in the present invention is not particularly limited as long as it is commonly used in the fields of cosmetics and pharmaceuticals. For example, methanol, ethanol, propanol, isopropanol, butanol, isobutanol and the like are used. Lower alcohol having 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms; propylene glycol, dipropylene glycol, glycerin, 1,3-butylene glycol, butylene glycol, concentrated glycerin, polyethylene glycol, maltitol, mannitol, sorbitol, etc. Examples include polyhydric alcohols. these May be used alone or in combination of two or more. The lower alcohol may be anhydrous or hydrated. In the present invention, it is preferable to use (hydrous) ethanol, absolute ethanol, or isopropanol!
[0018] 本発明の皮膚外用組成物におけるアルコールの配合量は、 0〜45重量%程度、 好ましくは 4〜40重量%程度、より好ましくは 4〜35重量%程度である。 [0018] The blending amount of alcohol in the composition for external use of the present invention is about 0 to 45% by weight, preferably about 4 to 40% by weight, more preferably about 4 to 35% by weight.
[0019] 本発明の皮膚外用組成物における BHTとアルコールの配合比率は、 BHTを 1重 量部とした場合、アルコールが約 3重量部以下、好ましくは約 2重量部以下、より好ま しくは約 1重量部以下である。このような配合比率であれば、 BHTの固体状態を維持 することができ、かつ適度な刺激を皮膚に与えることができる。 The blending ratio of BHT and alcohol in the external composition for skin of the present invention is such that when BHT is 1 part by weight, alcohol is about 3 parts by weight or less, preferably about 2 parts by weight or less, and more preferably about 1 part by weight or less. With such a blending ratio, the solid state of BHT can be maintained and an appropriate stimulus can be given to the skin.
[0020] 本発明の皮膚外用組成物には、必要に応じて水、水溶性高分子等を配合してもよ い。水溶性高分子としては、従来公知のものを使用することができる力 例えばカル ボキシビニノレポリマー、ポリビニルアルコール、ポリビニルメチルエーテル、ポリビニノレ キシェチルセルロース、プルラン、寒天、ゼラチン、アルギン酸及びその塩、カラギー ナン、ガム類等が挙げられる。これらを 1種単独で使用してもよぐ 2種以上を組み合 わせて用いてもよい。 [0020] The external composition for skin of the present invention may contain water, a water-soluble polymer, or the like, if necessary. Conventionally known water-soluble polymers can be used, for example, carboxyvininole polymer, polyvinyl alcohol, polyvinyl methyl ether, polyvinylinoxychetyl cellulose, pullulan, agar, gelatin, alginic acid and its salts, carrageen Examples include naan and gums. These may be used alone or in combination of two or more.
[0021] 本発明の皮膚外用組成物における水の配合量は、 25〜89. 5重量%程度、好まし くは 27〜80. 2重量%程度、より好ましくは 28〜75重量%程度;水溶性高分子の配 合量は、 0. 5〜5重量%程度、好ましくは 0. 8〜4重量%程度、より好ましくは 1〜3 重量%程度である。 [0021] The amount of water in the external composition for skin of the present invention is about 25 to 89.5% by weight, preferably about 27 to 80.2% by weight, more preferably about 28 to 75% by weight; The amount of the conductive polymer to be combined is about 0.5 to 5% by weight, preferably about 0.8 to 4% by weight, and more preferably about 1 to 3% by weight.
[0022] 本発明の典型的な処方例としては、 BHTを 10〜40重量0 /0、ァノレコーノレを 0〜45 重量%、水溶性高分子を 0. 5〜5重量%、水 25〜89. 5重量%含有する皮膚外用 組成物が例示される。 [0022] Typical formulation examples of the present invention, 10 to 40 weight BHT 0/0, the Anorekonore 0-45 wt%, a water-soluble polymer 0.5 to 5% by weight, water 25-89. A composition for external use containing 5% by weight is exemplified.
[0023] 本発明の皮膚外用組成物には、上記以外にも必要に応じて、化粧料、医薬部外品 、医薬品に一般的に用いられる各種成分、水性成分、油性成分、保湿成分、賦形剤 、増粘剤、防腐剤、酸化防止剤、 pH調整剤、担体、香料、色剤、薬剤等を単独又は 2種以上を混合と組み合わせて各種剤型に調製することもできる。また、本発明の皮 膚外用組成物には、本発明の効果を損なわない範囲内で、公知の局所麻酔剤、消
炎剤等を含んでもよぐ例えば、リドカイン、ジブ力イン、塩酸ジブ力イン、ジフェンヒド ラミン、ァミノ安息香酸ェチル、デシットテシチン等の局所麻酔剤;マレイン酸クロルフ ェニラミン、ジフェンヒドラミン、塩酸ジフェンヒドラミン、グリチルレチン酸、グリチルリチ ン酸ニカリウム、グリチルリチン酸モノアンモニゥム、アラントイン、サリチル酸メチル等 の消炎剤; 1ーメントーノレ、 dl—メントーノレ、カンフル、 dl—力ンフノレ、乳酸メンチル等の 清涼化剤;尿素、サリチル酸、ヒアルロン酸ナトリウム等の保湿剤;イソプロピルメチル フエノール、第四級アンモニゥム塩 (塩化ベンザルコニゥム、塩化べンゼトニゥムなど) 、塩酸クロルへキシジン、スルフアジアジン等の殺菌剤;硝酸ォキシコナゾール、塩酸 ブテナフィン、塩酸ァモロルフイン、塩酸テルビナフイン、ラノコナゾール等の抗真菌 剤;トウガラシチンキ、カブサイシン等の温熱成分等が挙げられる。 [0023] In addition to the above, the composition for external use of the skin of the present invention includes various components generally used in cosmetics, quasi-drugs, pharmaceuticals, aqueous components, oil-based components, moisturizing components, moisturizing components, and so on. Forms, thickeners, preservatives, antioxidants, pH adjusters, carriers, fragrances, colorants, drugs and the like can be prepared in various dosage forms alone or in combination of two or more. In addition, the composition for external use of the skin of the present invention includes a known local anesthetic and antibacterial agent within the range not impairing the effects of the present invention. For example, local anesthetics such as lidocaine, dibu force in, dibu force in hydrochloride, diphenhydramine, ethyl aminobenzoate, desitthecin; chlorpheniramine maleate, diphenhydramine, diphenhydramine hydrochloride, glycyrrhetinic acid, glycyrrhizin Anti-inflammatory agents such as dipotassium phosphate, monoammonium glycyrrhizinate, allantoin, methyl salicylate; 1-menthol nole, dl-menthol nole, camphor, dl-strengthen, lactic acid menthylate, etc .; Moisturizers such as urea, salicylic acid, sodium hyaluronate Bactericides such as isopropylmethyl phenol, quaternary ammonium salts (benzalkonium chloride, benzethonium chloride, etc.), chlorhexidine hydrochloride, sulfadiazine, etc .; oxyconazole nitrate, butenaf hydrochloride Emissions, hydrochloric Amororufuin, hydrochloric Terubinafuin, antifungal agents such as lanoconazole; capsicum tincture, and the like thermal components such Kabusaishin.
[0024] 本発明の皮膚外用組成物の剤型としては、使用方法や適用部分に従って従来公 知の剤型に調製することができる力 S、例えば、軟膏、ローション、ゲル、エアゾール剤 等が挙げられる。 [0024] Examples of the dosage form of the external composition for skin of the present invention include force S that can be prepared into a conventionally known dosage form according to the method of use and application, such as an ointment, lotion, gel, aerosol, and the like. It is done.
[0025] 本発明の皮膚外用組成物には、所望の剤型とするための基剤が適当量含有される 。例えば、これに限られるものではないが、パラフィン、ワセリン、スクヮラン、ノ ラフィン 、 白ロウ、プラスチベース、ポリエチレングリコーノレ、マクロゴーノレ、ラウロマクロゴーノレ 、シリコン油、シリコン、ポリソルベート、ポリオキシエチレン硬化ヒマシ油、ォリーブ油 、綿実油、大豆油、ヤシ油などの油系基剤;セタノール、ステアリルアルコールなどの 高級アルコール;脂肪酸エステル (ミリスチン酸イソプロピル、ソルビタン脂肪酸エステ ルなど)、高級脂肪酸塩型乳化剤、高度精製卵黄レシチン、大豆レシチン、精製大 豆レシチン、サラシミツロウ、プロピレンカーボネート、卵黄リン脂質、卵黄油、ヤシ油 脂肪酸、ラウリル硫酸ナトリウム、その他イオン性、非イオン性界面活性剤などの乳化 剤;リン酸、酢酸、塩酸、水酸化ナトリウムなどの pH調整剤;液化石油ガス、ジメチノレ エーテルなどの噴射剤などが挙げられる。 [0025] The external composition for skin of the present invention contains an appropriate amount of a base for obtaining a desired dosage form. For example, but not limited to, paraffin, petrolatum, squalane, norafin, white wax, plastibase, polyethylene glycolenore, macrogonole, lauromacronore, silicone oil, silicone, polysorbate, polyoxyethylene hydrogenated castor oil, Oil bases such as olive oil, cottonseed oil, soybean oil, coconut oil; higher alcohols such as cetanol and stearyl alcohol; fatty acid esters (such as isopropyl myristate and sorbitan fatty acid ester), higher fatty acid salt emulsifiers, highly refined egg yolk lecithin , Soybean lecithin, refined soybean lecithin, white beeswax, propylene carbonate, egg yolk phospholipid, egg yolk oil, coconut oil fatty acid, sodium lauryl sulfate, other ionic and nonionic surfactants, etc .; phosphoric acid, acetic acid, salt PH adjusting agents such as acid and sodium hydroxide; propellants such as liquefied petroleum gas and dimethylol ether.
[0026] 本発明の皮膚外用組成物は、以上の成分を従来公知の方法に従って混合し、調 製すること力 Sできる。調製における温度、各成分の添加の順番、混合時間等の条件 は、各成分の物理的又は科学的性質、濃度、機器の応力等に応じ、当該分野の技 術常識に基づいて適宜設定することが特に限定されない。本発明の皮膚外用剤は、
例えば、水とアルコールそれぞれに溶解性の成分を溶解し、それらを混合、一様に 攪拌したものに、 BHTを最後に加えることにより調製することができる。 [0026] The composition for external use of the present invention can be prepared by mixing and preparing the above components according to a conventionally known method. Conditions such as temperature in preparation, order of addition of each component, mixing time, etc. should be set as appropriate based on the common general technical knowledge according to the physical or scientific properties of each component, concentration, instrument stress, etc. Is not particularly limited. The external preparation for skin of the present invention comprises For example, it can be prepared by dissolving components soluble in water and alcohol, mixing them and stirring them uniformly, and finally adding BHT.
[0027] 本発明の皮膚外用組成物は、鎮痒剤、水虫薬等として、かゆみを生じる箇所に適 用することが可能である。この目的において使用されるのであれば適用対象は特に 限定されないが、例えば、鎮痒剤として用いる場合、しっしん、虫さされ、乾燥肌、知 覚過敏肌等のかゆみを伴う症状に適用することができる。 [0027] The composition for external use of the skin of the present invention can be applied as an antipruritic agent, athlete's foot drug or the like to a place where itching occurs. The application target is not particularly limited as long as it is used for this purpose, but for example, when used as an antipruritic agent, it can be applied to symptom accompanied by itching, insect bite, dry skin, hypersensitive skin, etc. .
[0028] 本発明において「かゆみ」とは、前述のように「皮膚を搔破したいという観念を起こさ せる感覚」を指す。 [0028] In the present invention, "itch" refers to "a feeling that causes the idea of wanting to break through the skin" as described above.
[0029] 本発明の皮膚外用組成物を前記のかゆみの軽減を目的として使用する場合は、皮 膚のかゆい部分に本発明の皮膚外用組成物の適量を塗り広げればよい。塗り広げる ことによって、固体状態の BHTが皮膚のかゆい部分を物理的に刺激し、かゆみを刺 激感に置換し、更にぶりかえすことなくかゆみを抑制することができる。ここで、「かゆ みを刺激感に置換する」とは、短期的(瞬間的に)に皮膚感覚を「かゆみ」以外の刺 激 (搔いた感じ)を感じる状態にすることを指す。 [0029] When the external composition for skin of the present invention is used for the purpose of reducing the itching, an appropriate amount of the external composition for skin of the present invention may be spread over the itchy part of the skin. By spreading the coating, the solid BHT can physically irritate the itchy part of the skin, replace the itching with a feeling of irritation, and suppress the itching without further rebating. Here, “replacing itching with a sense of irritation” refers to making the skin sensation in a short-term (instantaneous) state of feeling an irritation (feeling itchy) other than “itching”.
[0030] また、本発明の皮膚外用剤による皮膚刺激は、皮膚を傷つけることなぐ適度な刺 激であるため、適用箇所の血行を促進するためなどに用いることが可能である。従つ て、本発明の皮膚外用剤は、マッサージ剤、外用消炎鎮痛剤等として用いることもで きる。 [0030] Further, the skin irritation by the external preparation for skin of the present invention is an appropriate stimulation without damaging the skin, and thus can be used for promoting blood circulation at the application site. Therefore, the external preparation for skin of the present invention can also be used as a massage agent, an external anti-inflammatory analgesic or the like.
実施例 Example
[0031] 以下に実施例等を示して本発明をより詳細に説明するが、本発明はこれらに限定さ れなレ、。 [0031] Hereinafter, the present invention will be described in more detail with reference to Examples and the like, but the present invention is not limited thereto.
[0032] 下記表 1に示される処方に基づいて各種成分を配合し、皮膚外用組成物を得た。 [0032] Based on the formulation shown in Table 1 below, various components were blended to obtain an external composition for skin.
表 1に規定される分量の水を一部採取し、そこにカルボキシビュルポリマーを攪拌し ながら徐々に添加した。これとは別に、表 1に規定される分量のアルコールの一部に 、 BHT (プチルヒドロキシトルエン:三栄化工株式会社)及び pH調整剤(トリエタノー ルァミン)以外の成分を加え、攪拌混合した。この溶液を、前記カルボキシビュルポリ マーを混合した水溶液に、攪拌しながら徐々に添加した。 pH調整剤(トリエタノール ァミン)を添加する場合は、水残部に pH調整剤を混合したものをさらに加えた。得ら
れた溶液を一定時間攪拌し、最後に BHTを加えてさらに攪拌し、皮膚外用組成物を 調製した。ここで、 BHTは、乳鉢中で粉砕し、各径を有する篩で分類したものを用い た。 A portion of the amount of water specified in Table 1 was sampled, and the carboxybule polymer was gradually added thereto with stirring. Separately, components other than BHT (Ptylhydroxytoluene: Sanei Chemical Co., Ltd.) and a pH adjuster (triethanolamine) were added to a part of the amount of alcohol specified in Table 1 and mixed with stirring. This solution was gradually added to the aqueous solution mixed with the carboxybutyl polymer while stirring. When adding a pH adjuster (triethanolamine), a mixture of the pH adjuster and the remaining water was further added. Obtained The resulting solution was stirred for a certain time, and finally BHT was added and further stirred to prepare a composition for external use on the skin. Here, BHT used was crushed in a mortar and classified by a sieve having each diameter.
[0033] 得られた皮膚外用組成物を常温 (約 25°C)にて 1週間保存した後、その性状を目視 により確認し、安定性を評価した。具体的には、分散性 (粒子の沈降や団粒化 (粒子 の凝集)の有無)、保型性 (粘度低下等の初期性状と比較した場合の明らかな変化の 有無)、粒子が固体の性状を維持しているかどうか (軟化、溶解の有無)について確 認した。これらの性状のいずれにも変化が無かった場合は〇とし、いずれか 1つでも 変化が確認された場合は Xとした。 [0033] The obtained external composition for skin was stored at room temperature (about 25 ° C) for 1 week, and its properties were visually confirmed to evaluate the stability. Specifically, dispersibility (presence / absence of particle settling and agglomeration (aggregation of particles)), shape retention (presence / absence of obvious changes compared to initial properties such as viscosity reduction), and particles are solid It was confirmed whether the properties were maintained (softening / dissolution). When there was no change in any of these properties, it was marked as ◯, and when any one of the changes was confirmed, it was marked as X.
[0034] また、安定性の評価結果が「〇」の皮膚外用組成物を、虫さされ等によるかゆみを 訴える被験者 10名の患部に塗布し、適用しやすさ(塗布しにくい場合を 1点、塗布し やすい場合を 5点)、かゆみの刺激感への置換 (刺激感に置換されない場合を 1点、 刺激感に置換された場合を 5点)および痒み止め効果 (かゆみが止まらなかった場合 を 1点、かゆみが止まった場合を 5点)に関し、各々 5段階で評価を行った。 [0034] In addition, the composition for external use with a stability evaluation result of “◯” was applied to the affected area of 10 subjects complaining of itching caused by insect bites, etc., and it was easy to apply (one point when it was difficult to apply) 5 points when easy to apply), replacement of itching with irritation (1 point when not replaced with irritation, 5 points when replaced with irritation) and anti-itching effect (when itching does not stop) 1 point and 5 points when itching stops) were evaluated in 5 stages each.
[0035] さらに、得られた皮膚外用組成物を健常者 10名の皮膚に塗布し、快適な物理的刺 激感 (感じない場合を 1点、感じた場合を 5点)に関し、 5段階で評価を行った。 [0035] Furthermore, the obtained composition for external application on skin was applied to the skin of 10 healthy subjects, and with regard to comfortable physical irritation (1 point when not felt, 5 points when felt) Evaluation was performed.
[0036] 各被験者による評点を合計し、合計点が 45〜50点:◎、 35〜45点:〇、 25〜35 点;△、 25点未満: Xとした。 [0036] The scores by each subject were totaled, and the total score was 45-50 points: ◎, 35-45 points: ◯, 25-35 points; Δ, less than 25 points: X.
[0037] これらの評価結果を表 1に示す。表中、 CVPはカルボキシビュルポリマー、 PGはプ ロピレングリコールを表す。 [0037] Table 1 shows the evaluation results. In the table, CVP represents carboxybulle polymer and PG represents propylene glycol.
[0038] [表 1]
[0038] [Table 1]
[0039] また、 BHT以外の粒子を配合した皮膚外用組成物(比較例;!〜 32)についても同 様に評価した。結果を下記表 2— 1及び表 2— 2に示す。 [0039] In addition, the composition for external use with skin containing particles other than BHT (Comparative Examples;! -32) was also evaluated in the same manner. The results are shown in Table 2-1 and Table 2-2 below.
[0040] 表中、 CVPはカルボキシビュルポリマー、 PGはプロピレングリコールを表す。 [0040] In the table, CVP represents a carboxybule polymer, and PG represents propylene glycol.
[0041] [表 2-1]
[0041] [Table 2-1]
[0042] [表 2-2]
[0042] [Table 2-2]
[0043] 表中、比較例;!〜 8、 14、 15、 17-24, 30及び 31は、組成物の安定性が悪く評価 できなかった。 [0043] In the table, Comparative Examples;! To 8, 14, 15, 17-24, 30 and 31 could not be evaluated due to poor stability of the compositions.
[0044] 比較例 9〜13、 16、 25〜29及び 32は、従来公知の粒子を配合した皮膚外用組成 物である。これらの皮膚外用剤は、比較的安定性は良力、つたものの、いずれも痒み の刺激感への置換作用および快適な刺激作用を有してレ、なレ、ことが示された。なお 、 BHTを溶解状態とした製剤では、痒みの刺激感への置換および快適な刺激感は 得られなかった(データ示さず)。 [0044] Comparative Examples 9 to 13, 16, 25 to 29, and 32 are compositions for external use in skin that contain conventionally known particles. These external preparations for skin were relatively stable and good, but all of them had a replacement effect on the irritating feeling of itchiness and a pleasant stimulating action. In the preparations in which BHT was dissolved, it was not possible to obtain a sensation of itchiness or a pleasant irritation (data not shown).
[0045] 一方、実施例;!〜 19の皮膚外用組成物は、いずれも安定性、皮膚への適用のしゃ すさに優れていることが示された。また、固体状態の BHTが配合されていることから、 皮膚に塗布することによって快適な刺激感を得られるものであり、かゆみ抑制効果、 かゆみを刺激感に置換する作用をも備えた皮膚外用剤であることが示された。特に 粒子径の異なる BHTを組み合わせて用いることにより、より優れた快適な刺激感、か ゆみ止め効果、かゆみを刺激感に置換する作用を発揮することが示された。 [0045] On the other hand, it was shown that all of the compositions for external use of skin in Examples;! To 19 were excellent in stability and softness to application to the skin. In addition, because it contains BHT in a solid state, it can provide a comfortable irritation feeling when applied to the skin, and it also has an anti-itching effect and an action to replace itching with irritation. It was shown that. In particular, it was shown that the combination of BHT with different particle sizes exerted a more comfortable and comfortable irritation, anti-itching effect, and the action of replacing itching with irritation.
[0046] かゆみは、物理的な刺激が加われば、かえって増強されることが知られている。しか しながら、本発明の皮膚外用組成物は、かゆみを刺激感に置換するという一時的な かゆみ抑制効果のみならず、優れたかゆみ止め効果を有することが示された。すな わち、本発明の皮膚外用組成物は、即効性かつ持続性のあるかゆみ抑制効果を有 するものである。 [0046] Itching is known that itching is enhanced when a physical stimulus is applied. However, it was shown that the composition for external use of the skin of the present invention has an excellent anti-itching effect as well as a temporary anti-itching effect of replacing itching with a stimulating feeling. That is, the external composition for skin of the present invention has an immediate and long-lasting itch suppression effect.
[0047] 以下に処方例を示す。表中、 CVPはカルボキシビュルポリマー、 PGはプロピレン グリコール、 HPCはヒドロキシプロピルセルロース、 DPGはジプロピレングリコール、 1 , 3— BGは 1 , 3—ブチレングリコールを表す。 [0047] Formulation examples are shown below. In the table, CVP represents carboxybutyl polymer, PG represents propylene glycol, HPC represents hydroxypropyl cellulose, DPG represents dipropylene glycol, and 1,3-BG represents 1,3-butylene glycol.
[0048] [表 3-1]
〔〕 D¾¾00934I [0048] [Table 3-1] [] D¾¾00934I
Claims
[1] 固体状態のプチルヒドロキシトルエン (以下、 BHTと示す)を含有することを特徴と する皮膚外用組成物。 [1] A composition for external use on skin, characterized by containing solid-state butyl hydroxytoluene (hereinafter referred to as BHT).
[2] BHTの粒子径が 1000 m以下であることを特徴とする請求項 1に記載の皮膚外 用組成物。 [2] The external composition for skin according to claim 1, wherein the particle size of BHT is 1000 m or less.
[3] 粒子径 350 111未満の BH丁、粒子径 350〜500 mの BH丁、粒子径 501〜; 100 [3] BH D with a particle size of less than 350 111, BH D with a particle size of 350-500 m, Particle size 501-;
0 mの BHTを 1種又は 2種以上組み合わせて配合することを特徴とする請求項 1又 は 2に記載の皮膚外用組成物。 The external composition for skin according to claim 1 or 2, wherein 0 m of BHT is used alone or in combination of two or more.
[4] BHTの含有量が 10〜40重量%である請求項 1〜3のいずれかに記載の皮膚外用 組成物。 [4] The external composition for skin according to any one of claims 1 to 3, wherein the BHT content is 10 to 40% by weight.
[5] さらに水溶性高分子を含有する、請求項 1〜4のいずれかに記載の皮膚外用組成 物。
[5] The external composition for skin according to any one of claims 1 to 4, further comprising a water-soluble polymer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006270076A JP5063072B2 (en) | 2006-09-29 | 2006-09-29 | Skin external composition |
JP2006-270076 | 2006-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008038807A1 true WO2008038807A1 (en) | 2008-04-03 |
Family
ID=39230237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/069111 WO2008038807A1 (en) | 2006-09-29 | 2007-09-28 | External composition for skin |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5063072B2 (en) |
WO (1) | WO2008038807A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2493955A (en) * | 2011-08-25 | 2013-02-27 | Hds Ltd | Methods and compositions for reducing allergic reactions to fragranced products and perfumes |
WO2021204568A1 (en) | 2020-04-07 | 2021-10-14 | Universität Basel | A topical composition for treatment of pruritus |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07126158A (en) * | 1993-10-27 | 1995-05-16 | Taisho Pharmaceut Co Ltd | Topical formulation containing crotamiton |
JPH07173078A (en) * | 1993-12-21 | 1995-07-11 | Taisho Pharmaceut Co Ltd | Antipruritic composition |
JPH1036883A (en) * | 1996-07-16 | 1998-02-10 | Asahi Chem Ind Co Ltd | Detergent composition for skin and hair |
JPH10330217A (en) * | 1997-05-29 | 1998-12-15 | Kose Corp | Skin whitening preparation for external use |
JPH11106307A (en) * | 1997-09-30 | 1999-04-20 | Pola Chem Ind Inc | Sulfite-containing soap |
JP2004256805A (en) * | 2003-02-07 | 2004-09-16 | Kao Corp | Framed soap composition |
WO2004078157A2 (en) * | 2003-03-04 | 2004-09-16 | The Procter & Gamble Company | Regulation of mammalian hair growth |
WO2005018320A1 (en) * | 2003-08-12 | 2005-03-03 | The William M. Yarbrough Foundation | Composition for treatment of biting and penetrating organisms and parasites, and urticaria and method of use |
-
2006
- 2006-09-29 JP JP2006270076A patent/JP5063072B2/en active Active
-
2007
- 2007-09-28 WO PCT/JP2007/069111 patent/WO2008038807A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07126158A (en) * | 1993-10-27 | 1995-05-16 | Taisho Pharmaceut Co Ltd | Topical formulation containing crotamiton |
JPH07173078A (en) * | 1993-12-21 | 1995-07-11 | Taisho Pharmaceut Co Ltd | Antipruritic composition |
JPH1036883A (en) * | 1996-07-16 | 1998-02-10 | Asahi Chem Ind Co Ltd | Detergent composition for skin and hair |
JPH10330217A (en) * | 1997-05-29 | 1998-12-15 | Kose Corp | Skin whitening preparation for external use |
JPH11106307A (en) * | 1997-09-30 | 1999-04-20 | Pola Chem Ind Inc | Sulfite-containing soap |
JP2004256805A (en) * | 2003-02-07 | 2004-09-16 | Kao Corp | Framed soap composition |
WO2004078157A2 (en) * | 2003-03-04 | 2004-09-16 | The Procter & Gamble Company | Regulation of mammalian hair growth |
WO2005018320A1 (en) * | 2003-08-12 | 2005-03-03 | The William M. Yarbrough Foundation | Composition for treatment of biting and penetrating organisms and parasites, and urticaria and method of use |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2493955A (en) * | 2011-08-25 | 2013-02-27 | Hds Ltd | Methods and compositions for reducing allergic reactions to fragranced products and perfumes |
WO2021204568A1 (en) | 2020-04-07 | 2021-10-14 | Universität Basel | A topical composition for treatment of pruritus |
Also Published As
Publication number | Publication date |
---|---|
JP5063072B2 (en) | 2012-10-31 |
JP2008088100A (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110403833B (en) | Compositions and methods for enhancing topical application of alkaline benefit agents | |
CA2567575C (en) | Organo-gel formulations for therapeutic applications | |
JP5694665B2 (en) | Topical preparation and its usage | |
JP4133837B2 (en) | Skin moisturizing gel and method | |
US20060078579A1 (en) | Organo-gel formulations for therapeutic applications | |
JP2009184951A (en) | External skin care preparation composition | |
JPH0215023A (en) | Anesthetic/skin humidifying composition and production thereof | |
JP2015530380A (en) | Composition for treating psoriasis | |
JP2000143486A (en) | Skin preparation for external use | |
JP2002212107A (en) | Topical composition | |
CN1357321A (en) | Inflammation and red spot reducing method | |
JP2012092067A (en) | Nonsteroidal anti-inflammatory analgesic agent for external use | |
WO2008038807A1 (en) | External composition for skin | |
EP1014926B1 (en) | Therapeutic and cosmetic compositions, their use and method for the preparation thereof | |
JP5565995B2 (en) | Antipruritic | |
WO2002036130A1 (en) | Veterinary composition for the topical treatment of traumatized or inflamed skin | |
JP7312527B2 (en) | emulsion composition | |
CN114746077A (en) | Personal care compositions and methods for using the same | |
KR102781432B1 (en) | Compositions for the recovery of joint pain and muscle pain using msm(methyl sulfonyl methane) and method for preparing thereof | |
JP7329910B2 (en) | Skin topical composition | |
JP7678657B2 (en) | Sebum secretion promoter | |
JPH08165244A (en) | Skin disease treatment | |
US20240180837A1 (en) | Method for Treating Inflammatory Skin Conditions and other Topical Conditions or Disorders | |
JP2022178149A (en) | external composition | |
JP2000143518A (en) | Preparation for external use for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07828852 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07828852 Country of ref document: EP Kind code of ref document: A1 |